Key facts
- Sinomune Pharmaceutical’s last known valuation is $300.5M (Aug 2021).
- It has raised $64.4M; the latest was PE Growth/Expansion ($42.5M) in Dec 2025.
- Notable investors include Jolmo Investment, Wuxi Capital, Sinovation Ventures, Cathay Capital, Wuxi Capital Group — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Sinomune Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Sinomune Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sinomune Pharmaceutical
Developer and manufacturer of pharmaceutical drugs with clinical value intended to specialize in the area of dermatology and nephrology. The company has a provincial engineering technology research center that develops products that are competitive in topical medications and tripterygium wilfordii fields, providing customers with skin topical medicine and tripterygium genus medicine.
- Sector
- Healthcare
- HQ
- Wuxi, China
- Founded
- 1999
- Employees
- 699
- Website
- sinomunepharma.com/
- Ownership
- Privately Held (backing)
Sinomune Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sinomune Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sinomune Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.